Differential induction of indoleamine-2,3-dioxygenase (IDO) by interferon-gamma in human gynecologic cancer cells.
Induction of indoleamine-2,3-dioxygenase (IDO) by interferon-gamma (IFN-gamma) is thought to be one mechanism underlying IFN-gamma's antineoplastic properties. Since clinical trials with IFN-gamma have yielded variable efficacy in treating cancers of gynecological origin, we tested the effects of IFN-gamma on cell growth and IDO activity in cell lines from seven gynecologic and five breast cancers. At a dose of 250 IU/ml, IFN-gamma suppressed cell growth and induced IDO activity in one cervical (C41), one vulva (A431), one breast (HS578T) and two ovarian (OVCAR-3, CAOV-3) cancer cell lines. Differing inhibition of cell growth, but with no induction of IDO activity, was found with IFN-gamma treatment of the other cell lines.
Leung
B S
BS
Department of Obstetrics and Gynecology, University of Minnesota Clinic and Hospital, Minneapolis 55455.
Stout
L E
LE
Shaskan
E G
EG
Thompson
R M
RM
D014408:Biomarkers, Tumor / Q000096:biosynthesis; D002455:Cell Division / Q000187:drug effects; D004790:Enzyme Induction; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D007371:Interferon-gamma / Q000494:pharmacology*; D007700:Kinetics; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D011994:Recombinant Proteins; D014366:Tryptophan Oxygenase / Q000096:biosynthesis* / Q000187:drug effects; D014407:Tumor Cells, Cultured
D014408:Biomarkers, Tumor; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D011994:Recombinant Proteins; D007371:Interferon-gamma; D014366:Tryptophan Oxygenase